Clinical Trials
8
Active:0
Completed:3
Trial Phases
3 Phases
Phase 1:2
Phase 2:4
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (50.0%)Not Applicable
2 (25.0%)Phase 1
2 (25.0%)Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Drug: HUYPS-1 nine tabletsDrug: HUYPS-1 one tablet
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05983328
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management
Phase 2
- Conditions
- Pain, Postoperative
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05842733
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Beitou District, Taiwan
A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers
Not Applicable
Recruiting
- Conditions
- HepatitisPharmacology
- Interventions
- Drug: SafeTynadol®
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05563961
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei City, Neihu District, Taiwan
To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05557448
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Beitou District, Taiwan
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04808154
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
- Prev
- 1
- 2
- Next
News
No news found